LECOZOTAN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H29N5O3
Molecular Weight	483.5616
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C[C@H](CN(C(=O)C1=CC=C(C=C1)C#N)C2=NC=CC=C2)N3CCN(CC3)C4=C5OCCOC5=CC=C4

InChI

InChIKey=NRPQELCNMADTOZ-OAQYLSRUSA-N

InChI=1S/C28H29N5O3/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23/h2-12,21H,13-18,20H2,1H3/t21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C28H29N5O3
Molecular Weight	483.5616
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

LECOZOTAN, a benzodioxanylpiperazine derivative, is a selective serotonin 1A receptor antagonist. It was in development for the symptomatic treatment of cognitive deficits in Alzheimer's disease.

Originator

Approval Year

PubMed

Show entries

Title	Date	PubMed
Progress update: Pharmacological treatment of Alzheimer's disease.	2007	19300586
A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease.	2008 Jan	17507923
Bilobalide modulates serotonin-controlled behaviors in the nematode Caenorhabditis elegans.	2009 Jun 22	19545409
Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.	2009 Mar	19523013
Drug development for Alzheimer's disease: recent progress.	2010 Dec	22110351